keyword
https://read.qxmd.com/read/37376729/laparoscopic-adrenalectomy-for-adrenal-tumors-with-endocrine-activity-perioperative-management-pathways-for-reduced-complications-and-improved-outcomes
#21
REVIEW
Takanobu Utsumi, Shota Iijima, Yuka Sugizaki, Takamichi Mori, Takatoshi Somoto, Seiji Kato, Ryo Oka, Takumi Endo, Naoto Kamiya, Hiroyoshi Suzuki
The major adrenal tumors with endocrine activity are primary aldosteronism, Cushing's syndrome/mild autonomous cortisol secretion, and pheochromocytoma/paraganglioma. Excessive aldosterone secretion in primary aldosteronism causes cardiovascular, renal, and other organ damage in addition to hypertension and hypokalemia. Cortisol hypersecretion in Cushing's syndrome/mild autonomous cortisol secretion causes obesity, hypertension, impaired glucose tolerance, and cardiometabolic syndrome. Massive secretion of catecholamines in pheochromocytoma/paraganglioma causes hypertension and cerebrocardiovascular disease due to rapid blood pressure fluctuation...
October 2023: International Journal of Urology: Official Journal of the Japanese Urological Association
https://read.qxmd.com/read/37328332/treatment-of-primary-aldosteronism-clinical-practice-guidelines-of-the-taiwan-society-of-aldosteronism
#22
REVIEW
Chi-Shin Tseng, Chieh-Kai Chan, Hsiang-Ying Lee, Chien-Ting Pan, Kang-Yung Peng, Shuo-Meng Wang, Kuo-How Huang, Yao-Chou Tsai, Vin-Cent Wu, Jeff S Chueh
Primary aldosteronism (PA) is the most common cause of secondary hypertension and one of the few medical diseases that can be cured by surgery. Excessive aldosterone secretion is highly associated with cardiovascular complications. Many studies have shown that patients with unilateral PA treated with surgery have better survival, cardiovascular, clinical, and biochemical outcomes than those who receive medical treatment. Consequently, laparoscopic adrenalectomy is the gold standard for treating unilateral PA...
June 14, 2023: Journal of the Formosan Medical Association
https://read.qxmd.com/read/37252566/comparison-of-the-effectiveness-and-safety-of-chlorthalidone-and-hydrochlorothiazide-in-patients-with-hypertension-a-meta-analysis
#23
REVIEW
Raja Ram Khenhrani, Ijeoma Nnodebe, Anurag Rawat, Rahul Adwani, Ammara Ghaffar, Sapna Devi, Muhammad Sohaib Afzal, Muhammad Usama
The aim of this study was to compare the effectiveness and safety of chlorthalidone and hydrochlorothiazide in patients with hypertension. The present meta-analysis was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Our search for relevant articles was conducted on PubMed, Scopus, and CINAHIL databases from their inception until March 31, 2023. Keywords used to search for relevant articles included "hydrochlorothiazide," "chlortalidone," "hypertension," "cardiovascular," and "blood pressure...
April 2023: Curēus
https://read.qxmd.com/read/37202237/strategies-for-subtyping-primary-aldosteronism
#24
REVIEW
Yun-Hsuan Yang, Yu-Ling Chang, Bo-Ching Lee, Ching-Chu Lu, Wei-Ting Wang, Ya-Hui Hu, Han-Wen Liu, Yung-Hsiang Lin, Chin-Chen Chang, Wan-Chen Wu, Fen-Yu Tseng, Yen-Hung Lin, Vin-Cent Wu, Chii-Min Hwu
Adrenal venous sampling (AVS) is a crucial method for the lateralization of primary aldosteronism (PA). It is advised to halt the use of the patient's antihypertensive medications and correct hypokalemia prior to undergoing AVS. Hospitals equipped to conduct AVS should establish their own diagnostic criteria based on current guidelines. If the patient's antihypertensive medications cannot be discontinued, AVS can be performed as long as the serum renin level is suppressed. The Task Force of Taiwan PA recommends using a combination of adrenocorticotropic hormone stimulation, quick cortisol assay, and C-arm cone-beam computed tomography to maximize the success of AVS and minimize errors by using the simultaneous sampling technique...
May 16, 2023: Journal of the Formosan Medical Association
https://read.qxmd.com/read/37170822/systematic-review-of-therapeutic-agents-and-long-term-outcomes-of-familial-hyperaldosteronism-type-1
#25
JOURNAL ARTICLE
Shu Ting Tan, Veronica Boyle, Marianne S Elston
BACKGROUND: Familial hyperaldosteronism type 1 (FH1), previously known as glucocorticoid-remediable aldosteronism, was the first identified monogenic cause of primary aldosteronism. Patients classically develop hypertension at a young age and are at risk of premature vascular complications. A systematic review of FH1 was performed to determine long-term treatment outcomes. METHODS: Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted searches with a patient/population, intervention, comparison and outcomes (PICO) framework using Embase, Medline, PubMed, Scopus, and Web of Science databases to identify patients with FH1 prescribed either no treatment with a minimum 3 months follow-up or medical treatment of at least 3 months duration...
July 2023: Hypertension
https://read.qxmd.com/read/37090394/comparison-of-efficacy-and-safety-of-angiotensin-receptor-neprilysin-inhibitors-in-patients-with-heart-failure-with-reduced-ejection-fraction-a-meta-analysis
#26
REVIEW
Muhammad Talha Haseeb, Muhammad Nouman Aslam, Fnu Avanteeka, Umar Abdul Rehman Khalid, Dewan Zubaer Ahmad, Mithum Senaratne, Bsher Almaalouli, Shamsha Hirani
The present meta-analysis was conducted to compare the safety and efficacy of angiontensin receptor neprilysin inhibitor (ARNI) with angiotensin receptor blockers (ARBs) and angiotensin-converting-enzyme inhibitors (ACEi) in patients with heart failure with reduced ejection fraction (HFrEF). This meta-analysis was conducted and reported in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement. Two authors carried out a scientific literature search on online databases, including EMBASE, PubMed, and the Cochrane Library...
March 2023: Curēus
https://read.qxmd.com/read/37087837/traumatic-brain-injury-electrolyte-levels-and-associated-outcomes-a-systematic-review
#27
REVIEW
Micah Ngatuvai, Brian Martinez, Matthew Sauder, George Beeton, Ryan Andrade, Piueti Maka, Chadwick P Smith, Lucy Kornblith, Adel Elkbuli
INTRODUCTION: Although it has been established that electrolyte abnormalities are a consequence of traumatic brain injury (TBI), the degree to which electrolyte imbalances impact patient outcomes has not been fully established. We aim to determine the impact of sodium, potassium, calcium, and magnesium abnormalities on outcomes in patients with TBI. METHODS: Four databases were searched for studies related to the impact of electrolyte abnormalities on outcomes for TBI patients...
September 2023: Journal of Surgical Research
https://read.qxmd.com/read/36971375/sodium-glucose-cotransporter-2-inhibitors-and-cardiovascular-clinical-outcomes-in-acute-heart-failure-a-narrative-review
#28
REVIEW
Ryan Rodriguez, Stephanie Dwyer Kaluzna
PURPOSE: This review describes the evidence from randomized controlled trials (RCTs) regarding the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular (CV) clinical outcomes when therapy is initiated during acute heart failure (HF). SUMMARY: SGLT2 inhibitors have become a cornerstone of guideline-directed medical therapy (GDMT) for type 2 diabetes mellitus, chronic kidney disease, and HF. Because of their ability to promote natriuresis and diuresis as well as other potentially beneficial CV effects, use of SGLT2 inhibitors has been investigated when therapy is initiated during hospitalization for acute HF...
June 22, 2023: American Journal of Health-system Pharmacy: AJHP
https://read.qxmd.com/read/36909062/continuous-infusion-versus-bolus-injection-of-loop-diuretics-for-patients-with-congestive-heart-failure-a-meta-analysis
#29
REVIEW
Jithin Karedath, Anim Asif, Niharika Tentu, Tafseer Zahra, Saima Batool, Meenakshi Sathish, Qudsia I Sandhu, Areeba Khan
Loop diuretics continue to be a crucial component of pharmacological treatment, to eliminate extra fluid and enhance symptom control in acute decompensated heart failure (ADHF). Understanding the loop diuretics' more efficient form of administration would be very beneficial in improving the management of people's ADHF, resulting in a quicker resolution of symptoms and a notable decrease in morbidity. To assess the outcomes of intravenous continuous infusion with bolus injection of loop diuretics for patients with ADHF, this meta-analysis was carried out...
February 2023: Curēus
https://read.qxmd.com/read/36881992/overcorrection-and-undercorrection-with-fixed-dosing-of-bolus-hypertonic-saline-for-symptomatic-hyponatremia
#30
JOURNAL ARTICLE
Anissa Pelouto, Julie C Refardt, Mirjam Christ-Crain, Adrienne A M Zandbergen, Ewout J Hoorn
OBJECTIVE: Current guidelines recommend treating symptomatic hyponatremia with rapid bolus-wise infusion of fixed volumes of hypertonic saline regardless of body weight. We hypothesize that this approach is associated with overcorrection and undercorrection in patients with low and high body weight. DESIGN: Single-center, retrospective cohort study. METHODS: Data were collected on patients treated with ≥1 bolus 100 or 150 mL 3% NaCl for symptomatic hyponatremia between 2017 and 2021...
March 2, 2023: European Journal of Endocrinology
https://read.qxmd.com/read/36827468/screening-for-primary-aldosteronism-among-hypertensive-adults-with-obstructive-sleep-apnea-a-retrospective-population-based-study
#31
JOURNAL ARTICLE
Gregory L Hundemer, Haris Imsirovic, Tetyana Kendzerska, Anand Vaidya, Alexander A Leung, Gregory A Kline, Rémi Goupil, François Madore, Mohsen Agharazii, Greg Knoll, Manish M Sood
BACKGROUND: Hypertension plus obstructive sleep apnea (OSA) is recommended in some guidelines as an indication to screen for primary aldosteronism (PA), yet prior data has brought the validity of this recommendation into question. Given this context, it remains unknown whether this screening recommendation is being implemented into clinical practice. METHODS: We conducted a population-based retrospective cohort study of all adult Ontario (Canada) residents with hypertension plus OSA from 2009-2020 with follow-up through 2021 utilizing provincial health administrative data...
February 24, 2023: American Journal of Hypertension
https://read.qxmd.com/read/36688209/management-for-electrolytes-disturbances-during-continuous-renal-replacement-therapy
#32
REVIEW
Song In Baeg, Kyungho Lee, Junseok Jeon, Hye Ryoun Jang
Despite the lack of proven superiority in mortality compared to intermittent hemodialysis, continuous renal replacement therapy (CRRT) is the preferred renal replacement therapy modality for critically ill patients with acute kidney injury (AKI) due to better hemodynamic stability and steady correction of electrolytes disturbances and volume overload. Multiple and complex electrolyte disorders in patients with AKI can be managed effectively with CRRT because controlled and predictable correction is feasible...
December 2022: Electrolyte & Blood Pressure: E & BP
https://read.qxmd.com/read/36271676/pairwise-comparison-of-hydrochlorothiazide-and-chlorthalidone-responses-among-hypertensive-patients
#33
JOURNAL ARTICLE
Lakshmi Manasa S Chekka, Rhonda M Cooper-DeHoff, John G Gums, Arlene B Chapman, Julie A Johnson
This study conducted a pairwise comparison of antihypertensive and metabolic effects of hydrochlorothiazide (HCTZ) and chlorthalidone (CTD) at 25 mg/day in the same individuals to address the clinical dilemma on preferred thiazide for hypertension (HTN) management. We included 15 African American (AA) and 35 European American (EA) patients with HTN treated with HCTZ and CTD as part of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) and PEAR-2 trials, respectively. Mean reduction in systolic/diastolic blood pressure (SBP/DBP) with HCTZ versus CTD was 8/5 versus 16/8 mmHg among EA patients (p < 1...
October 21, 2022: Clinical and Translational Science
https://read.qxmd.com/read/36260162/acute-kidney-injury-during-cisplatin-therapy-and-associations-with-kidney-outcomes-2-to-6%C3%A2-months-post-cisplatin-in-children-a-multi-centre-prospective-observational-study
#34
MULTICENTER STUDY
Kelly R McMahon, Asaf Lebel, Shahrad Rod Rassekh, Kirk R Schultz, Tom D Blydt-Hansen, Geoffrey D E Cuvelier, Cherry Mammen, Maury Pinsk, Bruce C Carleton, Ross T Tsuyuki, Colin J D Ross, Louis Huynh, Mariya Yordanova, Frédérik Crépeau-Hubert, Stella Wang, Ana Palijan, Jasmine Lee, Debbie Boyko, Michael Zappitelli
BACKGROUND: Few studies describe acute kidney injury (AKI) burden during paediatric cisplatin therapy and post-cisplatin kidney outcomes. We determined risk factors for and rate of (1) AKI during cisplatin therapy, (2) chronic kidney disease (CKD) and hypertension 2-6 months post-cisplatin, and (3) whether AKI is associated with 2-6-month outcomes. METHODS: This prospective cohort study enrolled children (aged < 18 years at cancer diagnosis) treated with cisplatin from twelve Canadian hospitals...
May 2023: Pediatric Nephrology
https://read.qxmd.com/read/36198493/implementation-of-a-formal-sleep-center-based-screening-protocol-for-primary-aldosteronism-in-patients-with-obstructive-sleep-apnea
#35
JOURNAL ARTICLE
Kyla Wright, Mandana Mahmoudi, Nidhi Agrawal, Hope Simpson, Michael S Lui, H Leon Pachter, Kepal Patel, Jason Prescott, Insoo Suh
BACKGROUND: There is a bidirectional association between primary aldosteronism and obstructive sleep apnea, with evidence suggesting that the treatment of primary aldosteronism can reduce obstructive sleep apnea severity. Current guidelines recommend screening for primary aldosteronism in patients with comorbid hypertension and obstructive sleep apnea, identifying potential candidates for treatment. However, emerging data suggest current screening practices are unsatisfactory. Moreover, data regarding the true incidence of primary aldosteronism among this population are limited...
October 2, 2022: Surgery
https://read.qxmd.com/read/36196469/who-should-be-screened-for-primary-aldosteronism-a-comprehensive-review-of-current-evidence
#36
REVIEW
Wei-Chieh Huang, Yen-Hung Lin, Vin-Cent Wu, Chen-Huan Chen, Saulat Siddique, Yook-Chin Chia, Jam Chin Tay, Guruprasad Sogunuru, Hao-Min Cheng, Kazuomi Kario
Arterial hypertension is a major risk factor for cardiovascular disease. The prevalence of primary aldosteronism (PA) ranges from 5% to 10% in the general hypertensive population and is regarded as one of the most common causes of secondary hypertension. There are two major causes of PA: bilateral adrenal hyperplasia and aldosterone-producing adenoma. The diagnosis of PA comprises screening, confirmatory testing, and subtype differentiation. The Endocrine Society Practice Guidelines for the diagnosis and treatment of PA recommends screening of patients at an increased risk of PA...
September 2022: Journal of Clinical Hypertension
https://read.qxmd.com/read/36195682/whole-exome-sequencing-identified-a-novel-splice-donor-site-variant-in-interleukin-2-receptor-alpha-chain
#37
JOURNAL ARTICLE
Nadia Waheed, Maryam Naseer, Nighat Haider, Sufyan Suleman, Asmat Ullah
Interleukin 2 receptor alpha chain (IL-2Rα or CD25) deficiency (OMIM #606367) is an immune dysregulation disorder segregating in autosomal recessive form. The disease is caused by biallelic variants in the IL-2Rα gene encoding IL-2Rα also known as CD25 protein. IL-2Rα combines with γ and β chains of interleukin 2 receptor to form a functional interleukin 2 receptor (IL-2R). In the present study, we identified a Pakistani family presenting a unique presentation of IL-2Rα deficiency. Clinical whole exome sequencing revealed a novel splice donor site variant (NM_001378789...
October 4, 2022: Immunogenetics
https://read.qxmd.com/read/36027140/effects-of-mineralocorticoid-receptor-antagonists-on-aldosterone-to-renin-ratio-in-patients-with-primary-aldosteronism
#38
JOURNAL ARTICLE
Alessio Pecori, Fabrizio Buffolo, Jacopo Burrello, Giulio Mengozzi, Francesca Rumbolo, Valeria Avataneo, Antonio D'Avolio, Franco Rabbia, Chiara Bertello, Franco Veglio, Paolo Mulatero, Silvia Monticone
OBJECTIVE: Current guidelines recommend to withdraw interfering antihypertensive drugs before to perform a screening test for primary aldosteronism (PA). Recent studies suggested that diagnostic work-up of PA might be performed without withdrawing mineralocorticoid receptor antagonist (MRA) treatment in selected patients, especially when severe hypertension and hypokalemia are difficult to control.We designed a prospective study to evaluate the effects of MRA treatment on aldosterone to renin ratio (ARR) in patients with PA...
June 1, 2022: Journal of Hypertension
https://read.qxmd.com/read/36002784/treatment-of-cushing-s-syndrome-with-osilodrostat-practical-applications-of-recent-studies-with-case-examples
#39
REVIEW
Maria Fleseriu, Beverly M K Biller
Endogenous Cushing's syndrome (CS) is a rare endocrine condition frequently caused by a tumor resulting in elevated cortisol levels. Cushing's disease (CD) caused by an adrenocorticotropic hormone-secreting pituitary adenoma is the most common form of endogenous CS. Medical therapy for CD is mostly used as second-line treatment after failed surgery or recurrence and comprises several pituitary-directed drugs, adrenal steroidogenesis inhibitors, and a glucocorticoid receptor blocker, some of which are US Food and Drug Administration (FDA)-approved for this condition...
December 2022: Pituitary
https://read.qxmd.com/read/35845561/targeting-calcineurin-inhibitor-induced-arterial-hypertension-in-liver-transplanted-children-using-hydrochlorothiazide
#40
JOURNAL ARTICLE
Steffen Hartleif, Hannah Baier, Matthias Kumpf, Rupert Handgretinger, Alfred Königsrainer, Silvio Nadalin, Ekkehard Sturm
OBJECTIVE: Arterial hypertension (AH) is the most common toxic effect of calcineurin inhibitor (CNI)-based immunosuppression in children after liver transplantation (LT). Activation of the renal sodium chloride cotransporter (NCC) by CNIs has been described as a major cause of CNI-induced AH. Thiazides, for example, hydrochlorothiazide (HCTZ), can selectively block the NCC and may ameliorate CNI-induced AH after pediatric LT. METHODS: From 2005 thru 2015 we conducted a retrospective, single-center analysis of blood pressure in 2 pediatric cohorts (each n = 33) with or without HCTZ in their first year after LT...
2022: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
keyword
keyword
73655
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.